Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure

Hiteshkumar Soni, Praful P. Patel, Savan Patel, Akshyaya C. Rath, Aviseka Acharya, Harshkant D. Trivedi, Mukul R. Jain

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The aim was to investigate the nephroprotective effect of combination of aliskiren (ASK), a direct renin inhibitor and pentoxifylline (PTX), inhibitor of tumor necrotic factor-alpha (TNF-alpha), in rat remnant kidney model of chronic kidney disease (CKD). Materials and Methods: Nephrectomized (NPX) rats were treated with ASK (10 mg/ kg, p.o.), PTX (100 mg/kg, p.o.), and combination of PTX + ASK once daily for 28 days. We have performed analysis of various renal injury parameters after 4 weeks of treatment. Results: Treatment with PTX, ASK and combination showed significant improvement in urea, creatinine and total protein in plasma when compared with vehicle treated group in NPX rats. ASK and combination of PTX + ASK elicited significant reduction in blood pressure but PTX alone did not produce blood pressure reduction. ASK treatment showed significant elevation in TNF-alpha, whereas PTX and ASK + PTX showed significant reduction in TNF-alpha in plasma. Histopathologically, the extent of the kidney injury was similar in NPX + vehicle and NPX + ASK-treated rats. PTX and ASK + PTX-treated group showed lesser extent of kidney injury. There was good correlation of mRNA expression levels of kidney injury molecule-1 and bradykinin B1 receptor data with histopathological findings in kidney samples and elevated TNF-alpha levels in plasma. Conclusions: We conclude that combination of PTX + ASK may be better therapeutic intervention for nephroprotection in CKD patients.

Original languageEnglish (US)
Pages (from-to)80-85
Number of pages6
JournalIndian Journal of Pharmacology
Volume47
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pentoxifylline
Chronic Kidney Failure
Kidney
Wounds and Injuries
Chronic Renal Insufficiency
Neoplasms
Bradykinin B1 Receptors
aliskiren
Blood Pressure
Therapeutics
Renin
Urea
Blood Proteins
Creatinine

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure. / Soni, Hiteshkumar; Patel, Praful P.; Patel, Savan; Rath, Akshyaya C.; Acharya, Aviseka; Trivedi, Harshkant D.; Jain, Mukul R.

In: Indian Journal of Pharmacology, Vol. 47, No. 1, 01.01.2015, p. 80-85.

Research output: Contribution to journalArticle

Soni, Hiteshkumar ; Patel, Praful P. ; Patel, Savan ; Rath, Akshyaya C. ; Acharya, Aviseka ; Trivedi, Harshkant D. ; Jain, Mukul R. / Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure. In: Indian Journal of Pharmacology. 2015 ; Vol. 47, No. 1. pp. 80-85.
@article{188c14c4235549bf8c3079a4292ebdee,
title = "Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure",
abstract = "Objectives: The aim was to investigate the nephroprotective effect of combination of aliskiren (ASK), a direct renin inhibitor and pentoxifylline (PTX), inhibitor of tumor necrotic factor-alpha (TNF-alpha), in rat remnant kidney model of chronic kidney disease (CKD). Materials and Methods: Nephrectomized (NPX) rats were treated with ASK (10 mg/ kg, p.o.), PTX (100 mg/kg, p.o.), and combination of PTX + ASK once daily for 28 days. We have performed analysis of various renal injury parameters after 4 weeks of treatment. Results: Treatment with PTX, ASK and combination showed significant improvement in urea, creatinine and total protein in plasma when compared with vehicle treated group in NPX rats. ASK and combination of PTX + ASK elicited significant reduction in blood pressure but PTX alone did not produce blood pressure reduction. ASK treatment showed significant elevation in TNF-alpha, whereas PTX and ASK + PTX showed significant reduction in TNF-alpha in plasma. Histopathologically, the extent of the kidney injury was similar in NPX + vehicle and NPX + ASK-treated rats. PTX and ASK + PTX-treated group showed lesser extent of kidney injury. There was good correlation of mRNA expression levels of kidney injury molecule-1 and bradykinin B1 receptor data with histopathological findings in kidney samples and elevated TNF-alpha levels in plasma. Conclusions: We conclude that combination of PTX + ASK may be better therapeutic intervention for nephroprotection in CKD patients.",
author = "Hiteshkumar Soni and Patel, {Praful P.} and Savan Patel and Rath, {Akshyaya C.} and Aviseka Acharya and Trivedi, {Harshkant D.} and Jain, {Mukul R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.4103/0253-7613.150351",
language = "English (US)",
volume = "47",
pages = "80--85",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure

AU - Soni, Hiteshkumar

AU - Patel, Praful P.

AU - Patel, Savan

AU - Rath, Akshyaya C.

AU - Acharya, Aviseka

AU - Trivedi, Harshkant D.

AU - Jain, Mukul R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: The aim was to investigate the nephroprotective effect of combination of aliskiren (ASK), a direct renin inhibitor and pentoxifylline (PTX), inhibitor of tumor necrotic factor-alpha (TNF-alpha), in rat remnant kidney model of chronic kidney disease (CKD). Materials and Methods: Nephrectomized (NPX) rats were treated with ASK (10 mg/ kg, p.o.), PTX (100 mg/kg, p.o.), and combination of PTX + ASK once daily for 28 days. We have performed analysis of various renal injury parameters after 4 weeks of treatment. Results: Treatment with PTX, ASK and combination showed significant improvement in urea, creatinine and total protein in plasma when compared with vehicle treated group in NPX rats. ASK and combination of PTX + ASK elicited significant reduction in blood pressure but PTX alone did not produce blood pressure reduction. ASK treatment showed significant elevation in TNF-alpha, whereas PTX and ASK + PTX showed significant reduction in TNF-alpha in plasma. Histopathologically, the extent of the kidney injury was similar in NPX + vehicle and NPX + ASK-treated rats. PTX and ASK + PTX-treated group showed lesser extent of kidney injury. There was good correlation of mRNA expression levels of kidney injury molecule-1 and bradykinin B1 receptor data with histopathological findings in kidney samples and elevated TNF-alpha levels in plasma. Conclusions: We conclude that combination of PTX + ASK may be better therapeutic intervention for nephroprotection in CKD patients.

AB - Objectives: The aim was to investigate the nephroprotective effect of combination of aliskiren (ASK), a direct renin inhibitor and pentoxifylline (PTX), inhibitor of tumor necrotic factor-alpha (TNF-alpha), in rat remnant kidney model of chronic kidney disease (CKD). Materials and Methods: Nephrectomized (NPX) rats were treated with ASK (10 mg/ kg, p.o.), PTX (100 mg/kg, p.o.), and combination of PTX + ASK once daily for 28 days. We have performed analysis of various renal injury parameters after 4 weeks of treatment. Results: Treatment with PTX, ASK and combination showed significant improvement in urea, creatinine and total protein in plasma when compared with vehicle treated group in NPX rats. ASK and combination of PTX + ASK elicited significant reduction in blood pressure but PTX alone did not produce blood pressure reduction. ASK treatment showed significant elevation in TNF-alpha, whereas PTX and ASK + PTX showed significant reduction in TNF-alpha in plasma. Histopathologically, the extent of the kidney injury was similar in NPX + vehicle and NPX + ASK-treated rats. PTX and ASK + PTX-treated group showed lesser extent of kidney injury. There was good correlation of mRNA expression levels of kidney injury molecule-1 and bradykinin B1 receptor data with histopathological findings in kidney samples and elevated TNF-alpha levels in plasma. Conclusions: We conclude that combination of PTX + ASK may be better therapeutic intervention for nephroprotection in CKD patients.

UR - http://www.scopus.com/inward/record.url?scp=84923010388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923010388&partnerID=8YFLogxK

U2 - 10.4103/0253-7613.150351

DO - 10.4103/0253-7613.150351

M3 - Article

VL - 47

SP - 80

EP - 85

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 1

ER -